peptide analgesic

The **peptide analgesic** is a first-in-class, non-opioid therapeutic candidate under preclinical development by Sekkei Bio for the treatment of acute and chronic pain conditions, including painful diabetic neuropathy and diabetic complications. Designed using Sekkei Bio's proprietary *Sq-PROT* in silico peptide and protein design platform, the molecule is engineered to act as a multi-targeted ligand that selectively modulates multiple non-opioid pathways involved in nociceptive signaling. By targeting peripheral non-opioid receptors, the candidate aims to deliver robust pain relief without the central nervous system side effects, tolerance, or addiction liabilities associated with traditional opioid therapies. Preclinical animal models have demonstrated significant analgesic efficacy and high selectivity over off-target receptors.

Other names

non-opiate peptide analgesicnon-opioid peptide analgesic